Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
CEL-SCI Corp. (CVM) is involved in the research and development of drugs and vaccines. The company's first and main, product, MULTIKINE, manufactured using the company's proprietary cell culture technologies, is a combination, or "cocktail", of natural human interleukin-2 (IL-2) and certain lymphokines and cytokines. MULTIKINE is being tested to determine how effective it is in improving the immune response of cancer patients. MULTIKINE has been tested in more than 190 patients in clinical trials conducted in the United States, Canada, Europe and Israel. Most of the patients were head and neck cancer patients, but some studies were also conducted in prostate cancer patients, HIV-infected patients and HIV-infected women with Human Papilloma Virus (HPV)-induced cervical dysplasia, the precursor stage before the development of cervical cancer. As of Sept. 30, 2002, CVM was conducting one additional Phase II head and neck cancer study and one study with HIV-infected women with HPV-induced cervical dysplasia. Results from the ongoing Phase I clinical trial of MULTIKINE in cervical dysplasia in HPV/HIV co-infected women indicated elimination or reduction of dysplasia in 71% of the patients, excellent treatment tolerance, and the confirmation of dysplasia elimination or reduction in severity by histopathology. Research and development expenses in FY 02 (Sept.) declined significantly because the company completed its production of MULTIKINE during the first quarter. During FY 02, the company instituted a cost reduction program and reduced its workforce significantly.
inderdaad: die heb ik porto!!! maak me wakker als de koers op 10 $$ staat!!! Goed zo spreuk
Ach als er personeel uitgaat dan weet je meestal wel hoe laat het is LOL :c)
CEL-SCI Corporation to Present at the 9th Annual LD Micro Invitational Business Wire Business Wire•June 3, 2019 VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4th at 10:40 a.m. PT. Geert Kersten, Chief Executive Officer of CEL-SCI, will be giving the presentation. Mr. Kersten’s presentation will be webcast and available in the Investor Relations section of the Company's website at cel-sci.com/new-investor-information/. The webcast will be archived for 90 days following the presentation. The conference will be held at the Luxe Sunset Boulevard Hotel in Los Angeles, California, will feature 250 companies in the small-cap / micro-cap space, and will be attended by over 1,000 individuals. About LD Micro LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. The firm hosts several influential conferences annually (Invitational, Summit, and Main Event). About CEL-SCI Corporation CEL-SCI believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study CEL-SCI treats patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck with Multikine* first, BEFORE they receive surgery, radiation and/or chemotherapy. This approach is unique. Most other cancer immunotherapies are administered only after conventional therapies have been tried and/or failed. Multikine (Leukocyte Interleukin, Injection), has received Orphan Drug designation from the FDA for the neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. CEL-SCI's Phase 3 study is the largest Phase 3 study in the world for the treatment of head and neck cancer. Per the study's protocol, newly diagnosed patients with advanced primary squamous cell carcinoma are treated with the Multikine treatment regimen for 3 weeks prior to the Standard of Care (SOC) which involves surgery, chemotherapy and/or radiation. Multikine is designed to help the immune system "see" the tumor at a time when the immune system is still relatively intact and thereby better able to mount an attack on the tumor. The aim of treatment with Multikine is to boost the body's immune system prior to SOC. The Phase 3 study is fully enrolled with 928 patients and the last patient was treated in September 2016, about 2.5 years ago. CEL-SCI is waiting for 298 events to occur for a final data readout. The Company's LEAPS technology is currently being developed as a therapeutic vaccine for rheumatoid arthritis and is supported by grants from the National Institutes of Health. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the terms, expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2018. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events
WENEN, Va .-- (BUSINESS WIRE) - CEL-SCI Corporation (NYSE American: CVM) , een Fase 3 immunotherapie van kanker, heeft vandaag aangekondigd dat het zal presenteren op de 9 e jaarlijkse LD Micro Invitational op dinsdag, juni 4 th op 10:40 PT. Geert Kersten, Chief Executive Officer van CEL-SCI, zal de presentatie geven. De presentatie van de heer Kersten zal worden webcast en beschikbaar zijn in de sectie Investor Relations van de website van de onderneming op cel-sci.com/new-investor-information/ . De webcast wordt 90 dagen na de presentatie gearchiveerd. De conferentie zal worden gehouden in het Luxe Sunset Boulevard Hotel in Los Angeles, Californië, zal 250 bedrijven in de small-cap / micro-cap ruimte bevatten, en zal worden bijgewoond door meer dan 1.000 personen. Over LD Micro LD Micro werd in 2006 opgericht met als enig doel een onafhankelijke hulpbron in de microcapruimte te zijn. Het bedrijf organiseert jaarlijks verschillende invloedrijke conferenties (Invitational, Summit en Main Event). Over CEL-SCI Corporation CEL-SCI is van mening dat het stimuleren van het immuunsysteem van een patiënt, terwijl het nog intact is, de grootst mogelijke impact op de overleving zou moeten hebben. Daarom behandelt CEL-SCI in de fase 3-studie patiënten die onlangs zijn gediagnosticeerd met gevorderd plaveiselcelcarcinoom van het hoofd en de nek eerst met multikine *, VOORDAT zij een operatie, bestraling en / of chemotherapie ondergaan. Deze aanpak is uniek. De meeste andere immuuntherapieën van kanker worden alleen toegediend nadat conventionele therapieën zijn geprobeerd en / of mislukt. Multikine (Leukocyte Interleukin, Injection), heeft de weesgeneesmiddel-aanduiding gekregen van de FDA voor de neoadjuvante therapie bij patiënten met plaveiselcelcarcinoom (kanker) van het hoofd en de nek. De Fase 3-studie van CEL-SCI is de grootste fase 3-studie ter wereld voor de behandeling van hoofd- en nekkanker. Volgens het protocol van de studie worden nieuw gediagnosticeerde patiënten met gevorderd plaveiselcelcarcinoom behandeld met het Multikine-behandelingsregime gedurende 3 weken voorafgaand aan de Standard of Care (SOC), die chirurgie, chemotherapie en / of bestraling omvat. Multikine is ontworpen om het immuunsysteem te helpen de tumor te "zien" op een moment dat het immuunsysteem nog steeds relatief intact is en daardoor beter in staat is om een ??aanval op de tumor uit te voeren. Het doel van de behandeling met Multikine is het stimuleren van het immuunsysteem van het lichaam voorafgaand aan de SOC. De fase 3-studie is volledig geïncludeerd bij 928 patiënten en de laatste patiënt werd behandeld in september 2016, ongeveer 2,5 jaar geleden. CEL-SCI wacht tot 298 gebeurtenissen plaatsvinden voor een laatste gegevensuitlezing. De LEAPS-technologie van het bedrijf wordt momenteel ontwikkeld als een therapeutisch vaccin voor reumatoïde artritis en wordt ondersteund door subsidies van de National Institutes of Health. Het bedrijf heeft vestigingen in Wenen, Virginia en in / nabij Baltimore, Maryland. Forward-looking Statements Dit persbericht bevat toekomstgerichte verklaringen in de zin van Sectie 27A van de Securities Act van 1933, zoals gewijzigd, en Sectie 21E van de Securities Exchange Act van 1934, zoals gewijzigd. Bij gebruik in dit persbericht zijn de woorden "beoogt", "gelooft", "verwacht", "plant" en "verwacht" en soortgelijke uitdrukkingen bedoeld om toekomstgerichte verklaringen te identificeren. Dergelijke verklaringen zijn onderhevig aan risico's en onzekerheden die ertoe kunnen leiden dat de werkelijke resultaten wezenlijk verschillen van de geprojecteerde. Dergelijke verklaringen omvatten, maar zijn niet beperkt tot, uitspraken over de voorwaarden, verwachte opbrengsten, gebruik van de opbrengsten en afsluiting van het aanbod. Factoren die dergelijke verschillen kunnen veroorzaken of ertoe kunnen bijdragen, zijn onder meer: ??een onvermogen om de klinische resultaten die in klinische studies zijn aangetoond, te dupliceren,
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
874,79
+0,96%
EUR/USD
1,0702
+0,47%
FTSE 100
8.044,81
+0,26%
Germany40^
18.161,70
+0,13%
Gold spot
2.322,91
-0,19%
NY-Nasdaq Composite
15.696,64
+1,59%
Stijgers
Dalers